{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:34:25Z","timestamp":1778726065523,"version":"3.51.4"},"reference-count":19,"publisher":"Digital Journal of Opthalmology","issue":"2","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digit J Ophthalmol"],"abstract":"<jats:p>Netarsudil is a relatively new medication for the treatment of primary open-angle glaucoma and ocular hypertension. It has been associated with red eyes and burning after instillation. Reticular epitheliopathy is a relatively rare complication of netarsudil that has been described in patients with preexisting corneal edema. We report the case of a healthy 76-year-old woman who developed reticular epitheliopathy after full-thickness penetrating keratoplasty that completely resolved following discontinuation of the medication. In cases where netarsudil is initiated for treatment of glaucoma or, off-label, endothelial dysfunction, reticular epithelial edema should be considered in patients complaining of a decline in vision and severe pain.<\/jats:p>","DOI":"10.5693\/djo.02.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T04:05:02Z","timestamp":1656389102000},"page":"34-37","source":"Crossref","is-referenced-by-count":11,"title":["Reticular epithelial edema after penetrating keratoplasty in a patient taking netarsudil"],"prefix":"10.5693","volume":"28","author":[{"given":"Lauren J.","family":"Jeang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit S.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon D.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonal S.","family":"Tuli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3822","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"JB","year":"2018","unstructured":"1. Serle JB, Katz LJ, McLaurin E, et al; ; ROCKET-1 and ROCKET-2 Study Groups. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-27.","journal-title":"Am J Ophthalmol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","article-title":"Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 Study","volume":"204","author":"Khouri","year":"2019","unstructured":"2. Khouri AS, Serle JB, Bacharach J, Usner DW, Lewis RA, Braswell P, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 Study. Am J Ophthalmol 2019;204:97-104.","journal-title":"Am J Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1167\/iovs.15-17595","article-title":"Effect of the Rho Kinase Inhibitor Y-27632 on corneal endothelial wound healing","volume":"56","author":"Okumura","year":"2015","unstructured":"3. Okumura N, Inoue R, Okazaki Y, Nakano S, Nakagawa H, Kinoshita S, et al. Effect of the Rho Kinase Inhibitor Y-27632 on corneal endothelial wound healing. Invest Ophthalmol Vis Sci 2015;56:6067-74.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Koizumi N, Okumura N, Ueno M, Kinoshita S. New therapeutic modality for corneal endothelial disease using Rho-associated kinase inhibitor eye drops. Cornea 2014;33 Suppl 11:S25-31.","DOI":"10.1097\/ICO.0000000000000240"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/ICO.0000000000001209","article-title":"Descemetorhexis without grafting for Fuchs endothelial dystrophy-supplementation with topical ripasudil","volume":"36","author":"Moloney","year":"2017","unstructured":"5. Moloney G, Petsoglou C, Ball M, Kerdraon Y, H\u00f6llhumer R, : N, et al. Descemetorhexis without grafting for Fuchs endothelial dystrophy-supplementation with topical ripasudil. Cornea 2017;36:642-8.","journal-title":"Cornea"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","article-title":"02% in patients with open-angle glaucoma or ocular hypertension","volume":"29","author":"Singh","year":"2020","unstructured":"6. Singh IP, Fechtner RD, Myers JS, Kim T, Usner DW, McKee H, et al. Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2020;29:878-84.","journal-title":"J Glaucoma"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","article-title":"Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy\/safety analysis of phase 3 MERCURY-1 and -2","volume":"37","author":"Asrani","year":"2020","unstructured":"7. Asrani S, Bacharach J, Holland E, McKee H, Sheng H, Lewis RA, et al. Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy\/safety analysis of phase 3 MERCURY-1 and -2. Adv Ther 2020;37:1620-31.","journal-title":"Adv Ther"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Chen H, McMillin JC, Frankfort BJ, Al-Mohtaseb Z. Reticular epithelial edema, an uncommon side effect of ROCK\/NET inhibitor netarsudil. J Glaucoma 2020;29:e124-e126.","DOI":"10.1097\/IJG.0000000000001636"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ajo.2020.04.002","article-title":"Reticular bullous epithelial edema in corneas treated with netarsudil: a case series","volume":"217","author":"Wisely","year":"2020","unstructured":"9. Wisely CE, Liu KC, Gupta D, Carlson AN, Asrani SG, Kim T. Reticular bullous epithelial edema in corneas treated with netarsudil: a case series. Am J Ophthalmol 2020;217:20-6.","journal-title":"Am J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/IJG.0000000000001516","article-title":"Reticular corneal edema or corneal honeycombing in eyes treated with netarsudil: a case series","volume":"29","author":"Moumneh","year":"2020","unstructured":"10. Moumneh K, Sheybani A, Fellman RL, Godfrey DG, Grover DS. Reticular corneal edema or corneal honeycombing in eyes treated with netarsudil: a case series. J Glaucoma 2020;29:607-10.","journal-title":"J Glaucoma"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.ophtha.2018.08.004","article-title":"Reticular epithelial edema in edematous corneas treated with netarsudil","volume":"125","author":"Fernandez","year":"2018","unstructured":"11. Fernandez MM. Reticular epithelial edema in edematous corneas treated with netarsudil. Ophthalmology. 2018;125:1709.","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1097\/ICO.0000000000002621","article-title":"Transient reticular cystic corneal epithelial edema with topical netarsudil: a case series and review","volume":"40","author":"LoBue","year":"2021","unstructured":"12. LoBue SA, Moustafa GA, Vu A, Amin M, Nguyen T, Goyal H. Transient reticular cystic corneal epithelial edema with topical netarsudil: a case series and review. Cornea 2021;40:1048-54.","journal-title":"Cornea"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ogla.2019.01.001","article-title":"Netarsudil-associated reticular corneal epithelial edema with raised intraocular pressure","volume":"2","author":"KC","year":"2019","unstructured":"13. Liu KC, Gupta D. Netarsudil-associated reticular corneal epithelial edema with raised intraocular pressure. Ophthalmol Glaucoma 2019;2:166.","journal-title":"Ophthalmol Glaucoma"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"100800","DOI":"10.1016\/j.ajoc.2020.100800","article-title":"Netarsudil-associated epithelial keratopathy","volume":"19","author":"Ramakrishnan","year":"2020","unstructured":"14. Ramakrishnan MS, Addis VM, Lehman AY, Sankar PS. Netarsudil-associated epithelial keratopathy. Am J Ophthalmol Case Rep 2020;19:100800.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Yin J, Yu FS. Rho kinases regulate corneal epithelial wound healing. Am J Physiol Cell Physiol 2008;295:C378-87.","DOI":"10.1152\/ajpcell.90624.2007"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/21541248.2014.973760","article-title":"Epithelial junctions and Rho family GTPases: the zonular signalosome","volume":"5","author":"Citi","year":"2014","unstructured":"16. Citi S, Guerrera D, Spadaro D, Shah J. Epithelial junctions and Rho family GTPases: the zonular signalosome. Small GTPases 2014;5:1-15.","journal-title":"Small GTPases"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Hopkins AM, Pineda AA, Winfree LM, Brown GT, Laukoetter MG, Nusrat A. Organized migration of epithelial cells requires control of adhesion and protrusion through Rho kinase effectors. Am J Physiol Gastrointest Liver Physiol 2007;292:G806-17.","DOI":"10.1152\/ajpgi.00333.2006"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ogla.2020.04.011","article-title":"Corneal hemorrhage associated with netarsudil in the setting of corneal neovascularization","volume":"3","author":"Asanad","year":"2020","unstructured":"18. Asanad S, Zhang R, Saeedi OJ. Corneal hemorrhage associated with netarsudil in the setting of corneal neovascularization. Ophthalmology Glaucoma 2020;3:392.","journal-title":"Ophthalmology Glaucoma"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Tanna AP, Esfandiari H, Teramoto K. Reversible corneal endothelial abnormalities with Netarsudil. J Glaucoma. 2020;29:e41-e3.","DOI":"10.1097\/IJG.0000000000001507"}],"container-title":["Digital Journal of Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/djo.harvard.edu\/index.php\/djo\/article\/download\/135\/130","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/djo.harvard.edu\/index.php\/djo\/article\/download\/135\/130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T14:19:36Z","timestamp":1680704376000},"score":1,"resource":{"primary":{"URL":"https:\/\/djo.harvard.edu\/index.php\/djo\/article\/view\/135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6,30]]}},"URL":"https:\/\/doi.org\/10.5693\/djo.02.2022.02.002","relation":{},"ISSN":["1542-8958"],"issn-type":[{"value":"1542-8958","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]}}}